诺华公司签署了20亿美元的收购Excellergy癌症治疗协议. Novartis signs $2B deal to acquire Excellergy for cancer therapies.

瑞士制药公司诺瓦蒂斯签署了一项价值高达20亿美元的协议, Swiss drugmaker Novartis has signed a deal worth up to $2 billion to acquire Excellergy, a clinical-stage biopharmaceutical company. 该协议授予诺华公司开发和商业化Excellergy的几种癌症治疗方法. The agreement grants Novartis rights to develop and commercialize several cancer therapies from Excellergy's pipeline.